The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 277-285

  Roubille, Franҫois ^a   Busseuil, David ^a   Shi, Yanfen ^a   Nachar, Walid ^a   Mihalache Avram, Téodora ^a   Mecteau, Mélanie ^a   Gillis, Marc Antoine ^a   Brand, Geneviève ^a   Théberge Julien, Gabriel ^a   Brodeur, Mathieu R ^a   Kernaleguen, Anne Elen ^a   Gombos, Mélania ^a   Rhéaume, Eric ^a,b   Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Carotid artery denudation; Endothelium; Gevokizumab; Interleukin 1 ; Neointima formation

Indexed keywords

EVANS BLUE; GEVOKIZUMAB; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY DISEASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ECHOGRAPHY; ENDOTHELIUM CELL; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; NEOINTIMA; NONHUMAN; RAT; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; AORTA; CAROTID ARTERY INJURIES; CELL CULTURE; CELL DIVISION; CELL MOTION; COMMON CAROTID ARTERY; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; REGENERATION; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AORTA; APOPTOSIS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION PROFILING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-1BETA; MALE; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REGENERATION; VASCULITIS;

EID: 84907085562     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.012     Document Type: Article

References (25)

1. Clowes A.W., Reidy M.A., Clowes M.M. Mechanisms of stenosis after arterial injury, laboratory investigation. J Tech Methods Pathol 1983, 49:208-215.
2. Chen Z., Sakuma M., Zago A.C., et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:709-714.
3. Park S.J., Kim H.S., Yang H.M., et al. Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. Arterioscler Thromb Vasc Biol 2004, 24:885-891.
4. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201:1355-1359.
5. Dinarello C.A., Wolff S.M. The role of interleukin-1 in disease. N Engl J Med 1993, 328:106-113.
6. Nicklin M.J., Hughes D.E., Barton J.L., et al. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000, 191:303-312.
7. Isoda K., Shiigai M., Ishigami N., et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation 2003, 108:516-518.
8. Wang X., Feuerstein G.Z., Gu J.L., et al. Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis 1995, 115:89-98.
9. Alexander M.R., Murgai M., Moehle C.W., et al. Interleukin-1beta modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-kappaB-dependent mechanisms. Physiol Genomics 2012, 44:417-429.
10. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
11. Yajima N., Takahashi M., Morimoto H., et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation 2008, 117:3079-3087.
12. Kirii H., Niwa T., Yamada Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:656-660.
13. Chi H., Messas E., Levine R.A., et al. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 2004, 110:1678-1685.
14. Elhage R., Maret A., Pieraggi M.T., et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998, 97:242-244.
15. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6:232-241.
16. Owyang A.M., Issafras H., Corbin J., et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. mAbs 2011, 3:49-60.
17. Roell M.K., Issafras H., Bauer R.J., et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 2010, 285:20607-20614.
18. Bhaskar V., Yin J., Mirza A.M., et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 2011, 216:313-320.
19. Toutouzas K., Colombo A., Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004, 25:1679-1687.
20. Asahara T., Bauters C., Pastore C., et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995, 91:2793-2801.
21. Kawabe-Yako R., Ii M., Masuo O., et al. Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. PLoS One 2011, 6:e24646.
22. Tersteeg C., Roest M., Mak-Nienhuis E.M., et al. A fibronectin-fibrinogen-tropoelastin coating reduces smooth muscle cell growth but improves endothelial cell function. J Cell Mol Med 2012, 16:2117-2126.
23. Kim D.W., Kwon J.S., Kim Y.G., et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004, 109:1558-1563.
24. Li H., Zhang L.J., Chen B.H., et al. Inhibitory effect of paclitaxel on endothelial cell adhesion and migration. Pharmacology 2010, 85:136-145.
25. Hayashi S., Yamamoto A., You F., et al. The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol 2009, 175:2226-2234.